Year All202520242023202220212020201920182017 Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency Apr 29, 2021 Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences Apr 28, 2021 Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics Apr 14, 2021 Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting Apr 08, 2021 Inozyme Pharma Expands its Scientific Advisory Board Apr 01, 2021 Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights Mar 25, 2021 The Balancing Act® on Lifetime to Feature ENPP1 Deficiency Mar 11, 2021 Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer Feb 04, 2021 Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency Jan 04, 2021 Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights Nov 12, 2020
Year All202520242023202220212020201920182017 Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency Apr 29, 2021 Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences Apr 28, 2021 Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics Apr 14, 2021 Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting Apr 08, 2021 Inozyme Pharma Expands its Scientific Advisory Board Apr 01, 2021 Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights Mar 25, 2021 The Balancing Act® on Lifetime to Feature ENPP1 Deficiency Mar 11, 2021 Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer Feb 04, 2021 Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency Jan 04, 2021 Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights Nov 12, 2020
Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency Apr 29, 2021
Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences Apr 28, 2021
Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics Apr 14, 2021
Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting Apr 08, 2021
Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights Mar 25, 2021
Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer Feb 04, 2021
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency Jan 04, 2021
Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights Nov 12, 2020